Daewoong pharmaceutical Co.,Ltd

069620.KS

069620.KSDaewoong pharmaceutical Co.,Ltd KR flag

KSE

130,000.00

KRW

+400.00

(+0.31%)

1.50TMarket Cap

Apr 28Next Earn

Upgrade to Unlock Non-US CompaniesTo view real-time data and analysis of companies outside of the United States, upgrade your account to our premium subscription.

Upgrade

Daewoong pharmaceutical Co.,Ltd

069620.KS

(KSE)

Recent

price

130,000.00

P/E

ratio

- -

div

yld

0.45%

ROIC.AI

Legends:

Stock price

Beta (1.0 Market)

% total return 04/28

Stock

S&P500

18.07

6.57

-23.30

22.75

19.82

93.55

2010	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	TTM
57,862.05	48,720.91	70,769.04	64,821.87	66,124.3	71,292.3	81,367.13	85,639.58	93,048.97	99,930.74	107,872.04	98,976.29	104,778.6	115,645.98	106,959.52	- -	123,608.95	Revenue per Share
4,663.56	1,677.82	4,998.42	3,302	5,658	3,056	4,160	2,613	3,060	-1,468	2,132	1,196	2,227	3,816	9,759.95	- -	2,149.04	Basic EPS, GAAP
6,970.69	-873.44	3,362.84	1,273.81	3,397.13	-2,229.27	-6,048.69	-14,326.98	695.97	-926.43	725.99	3,871.65	-3,162.51	443.2	1,216.14	- -	-15,422.9	Free Cash Flow per Basic Share
647.75	716.54	569.3	754.08	776.64	799.9	700.08	699.96	600.02	599.97	599.95	580.73	586.85	728.67	581.34	- -	39.52	Dividend per Share
23,319.23	24,677.25	29,843.32	31,202.54	36,044.96	37,467.06	41,259.51	43,171.28	45,635.63	42,702.68	44,824.27	45,179.59	45,104.56	48,175.81	59,241.64	- -	57,746.91	Book Value per Share
28,566.89	29,747.2	33,706.71	34,577.9	39,742.26	41,086.07	42,977.72	43,942.7	44,335.46	44,396.58	45,654.59	48,437.34	42,961.63	42,931.87	52,195.92	- -	50,416.82	Tangible Book Value per Share
11	10	10	10	10	10	10	10	10	10	10	11	11	11	11	- -	12	Basic Weighted Avg Shares
613,750	509,993	710,547	669,014	682,508	735,889	839,686	883,920	960,307	1,031,427	1,113,426	1,055,424	1,152,976	1,280,092	1,221,951	1,422,683	1,422,683	Sales/Revenue/Turnover
12.17	13.97	8.72	5.51	10.46	7.06	5.19	2.93	4.06	2.68	4.01	1.61	7.7	7.48	10.92	10.4	10.4	Operating Margin (%)
13,590	10,184	16,129	17,954	18,177	17,573	23,099	27,814	40,115	51,300	40,195	40,882	40,883	39,695	35,661	48,978	48,978	Depreciation Expense
49,467	17,563	50,186	34,079	58,400	31,544	42,930	26,970	31,581	-15,152	22,006	12,753	24,506	42,240	111,502	24,735	24,735	Net Income, GAAP
30.6	73.82	20.71	19.68	21.66	43.24	25.29	5.37	1.93	- -	- -	- -	- -	- -	0.12	58.72	58.72	Effective Tax Rate (%)
8.06	3.44	7.06	5.09	8.56	4.29	5.11	3.05	3.29	-1.47	1.98	1.21	2.13	3.3	9.12	1.74	1.74	Profit Margin (%)
188,863	136,527	124,794	151,924	224,923	324,107	303,668	284,626	250,083	148,265	264,176	201,601	59,742	76,137	-303,185	-16,623	-16,623	Working Capital
52,487	29,935	- -	- -	39,866	139,512	189,410	289,165	289,336	179,486	292,601	297,728	188,721	211,855	66,322	325,752	325,752	LT Debt
314,241	322,433	362,417	386,587	437,963	455,506	580,241	604,551	631,537	607,809	635,920	695,249	697,915	741,223	802,975	926,985	926,985	Total Equity
12.66	4.45	11.92	7.41	12.5	5.38	4.58	2.69	3.79	- -	- -	- -	- -	- -	11.09	4.38	7.85	Return on Invested Capital (%)
16.24	5.47	15.34	10.62	15.87	6.96	8.07	3.77	3.74	- -	- -	- -	- -	- -	11.19	2.27	3.99	Return on Capital (%)
21.86	6.95	17.99	10.96	16.83	8.31	10.57	6.19	6.89	-3.32	4.87	2.7	5.01	8.21	18.43	3.69	7.44	Return on Common Equity (%)

Capital Structure

•

in mil. unless spec.

Working Capital

•

in mil. unless spec.

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)	10 years	5 years	1 year
Sales/Revenue/Turnover	7.03%	5.39%	16.43%
Net Income, GAAP	-16.86%	41.73%	-77.82%
Free Cash Flow	-125.01%	-208.37%	-1,377.63%
Total Cash Common Dividend	- -	- -	16.55%
Total Equity	7.66%	7.94%	15.44%

Growth Rates

•

in mil. unless spec.

Quarterly Revenue

•

in mil. unless spec.

Quarterly Earnings Per Share

•

in mil. unless spec.

Quarterly Dividends Per Share

•

in mil. unless spec.

Similar Companies: BioSyent Inc. (BIOYF)
Novartis India Limited (NOVARTIND.BO)
Choom Holdings Inc. (CHOOF)
Together Pharma Ltd (TGTR.TA)
Cipher Pharmaceuticals Inc. (CPH.TO)
Red Light Holland Corp. (TRUFF)
Business: Daewoong Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical products in South Korea and internationally. It offers products in therapeutic areas, such as central nervous system, endocrinology, musculoskeletal, nephrology, antineoplastic, cardiovascular, gastrointestinal, metabolic, antiviral, analgesic, antacid, and digestive diseases, as well as wound, iron supplements, and muti-vitamins. The company also provides COVID-19 PCR kit, COVID-19 IgG/IgM RDT, and viral transport medium medical devices. The company was founded in 1945 and is headquartered in Seoul, South Korea.

2010	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	TTM
57,862.05	48,720.91	70,769.04	64,821.87	66,124.3	71,292.3	81,367.13	85,639.58	93,048.97	99,930.74	107,872.04	98,976.29	104,778.6	115,645.98	106,959.52	- -	123,608.95	Revenue per Share
4,663.56	1,677.82	4,998.42	3,302	5,658	3,056	4,160	2,613	3,060	-1,468	2,132	1,196	2,227	3,816	9,759.95	- -	2,149.04	Basic EPS, GAAP
6,970.69	-873.44	3,362.84	1,273.81	3,397.13	-2,229.27	-6,048.69	-14,326.98	695.97	-926.43	725.99	3,871.65	-3,162.51	443.2	1,216.14	- -	-15,422.9	Free Cash Flow per Basic Share
647.75	716.54	569.3	754.08	776.64	799.9	700.08	699.96	600.02	599.97	599.95	580.73	586.85	728.67	581.34	- -	39.52	Dividend per Share
23,319.23	24,677.25	29,843.32	31,202.54	36,044.96	37,467.06	41,259.51	43,171.28	45,635.63	42,702.68	44,824.27	45,179.59	45,104.56	48,175.81	59,241.64	- -	57,746.91	Book Value per Share
28,566.89	29,747.2	33,706.71	34,577.9	39,742.26	41,086.07	42,977.72	43,942.7	44,335.46	44,396.58	45,654.59	48,437.34	42,961.63	42,931.87	52,195.92	- -	50,416.82	Tangible Book Value per Share
11	10	10	10	10	10	10	10	10	10	10	11	11	11	11	- -	12	Basic Weighted Avg Shares
613,750	509,993	710,547	669,014	682,508	735,889	839,686	883,920	960,307	1,031,427	1,113,426	1,055,424	1,152,976	1,280,092	1,221,951	1,422,683	1,422,683	Sales/Revenue/Turnover
12.17	13.97	8.72	5.51	10.46	7.06	5.19	2.93	4.06	2.68	4.01	1.61	7.7	7.48	10.92	10.4	10.4	Operating Margin (%)
13,590	10,184	16,129	17,954	18,177	17,573	23,099	27,814	40,115	51,300	40,195	40,882	40,883	39,695	35,661	48,978	48,978	Depreciation Expense
49,467	17,563	50,186	34,079	58,400	31,544	42,930	26,970	31,581	-15,152	22,006	12,753	24,506	42,240	111,502	24,735	24,735	Net Income, GAAP
30.6	73.82	20.71	19.68	21.66	43.24	25.29	5.37	1.93	- -	- -	- -	- -	- -	0.12	58.72	58.72	Effective Tax Rate (%)
8.06	3.44	7.06	5.09	8.56	4.29	5.11	3.05	3.29	-1.47	1.98	1.21	2.13	3.3	9.12	1.74	1.74	Profit Margin (%)
188,863	136,527	124,794	151,924	224,923	324,107	303,668	284,626	250,083	148,265	264,176	201,601	59,742	76,137	-303,185	-16,623	-16,623	Working Capital
52,487	29,935	- -	- -	39,866	139,512	189,410	289,165	289,336	179,486	292,601	297,728	188,721	211,855	66,322	325,752	325,752	LT Debt
314,241	322,433	362,417	386,587	437,963	455,506	580,241	604,551	631,537	607,809	635,920	695,249	697,915	741,223	802,975	926,985	926,985	Total Equity
12.66	4.45	11.92	7.41	12.5	5.38	4.58	2.69	3.79	- -	- -	- -	- -	- -	11.09	4.38	7.85	Return on Invested Capital (%)
16.24	5.47	15.34	10.62	15.87	6.96	8.07	3.77	3.74	- -	- -	- -	- -	- -	11.19	2.27	3.99	Return on Capital (%)
21.86	6.95	17.99	10.96	16.83	8.31	10.57	6.19	6.89	-3.32	4.87	2.7	5.01	8.21	18.43	3.69	7.44	Return on Common Equity (%)

	Jun'24	Sep'24	Dec'24
Total Current Assets	589,613	574,231	612,792
Accounts Receivable, Net	165,477	146,553	160,742
Cash, Cash Equivalents & STI	110,314	107,511	116,347
Inventories	246,462	246,192	256,353
Total Current Liabilities	616,890	538,132	629,416
Payables & Accruals	- -	- -	- -
ST Debt	291,394	251,095	323,497
Deferred Revenue	- -	- -	- -

	Jun'24	Sep'24	Dec'24
ST Debt	291,394	251,095	323,497
LT Borrowings	259,255	337,340	324,478
LT Finance Leases	1,326	1,300	1,274
Preferred Equity and Hybrid Capital	- -	- -	- -
Shares Outstanding	12	12	12
Market Capitalization	1,172,868	1,584,037	1,454,807

Year	Q1	Q2	Q3	Q4	FY
2022	298,356	322,059	331,893	327,784	1,280,092
2023	322,415	350,191	340,900	- -	1,221,951
2024	335,785	360,545	358,473	367,880	1,422,683

Year	Q1	Q2	Q3	Q4	FY
2022	1,230	1,578	1,852	- -	3,816
2023	1,379	2,150	1,354	- -	9,759.95
2024	708	99	2,458	- -	- -

Year	Q1	Q2	Q3	Q4	FY
2022	50.7	600.76	0.91	- -	728.67
2023	- -	- -	55.56	- -	581.34
2024	- -	- -	38.86	- -	- -

Daewoong pharmaceutical Co.,Ltd

Growth Rates

(avg. rate of change)

Growth Rates

(avg. rate of change)

Working Capital

Capital Structure

Quarterly Revenue

Year

Quarterly Dividends Per Share

Year

Quarterly Earnings Per Share

Year